Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
TiVo Corporation Reports First Quarter 2019 Financial Results – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

TiVo Corporation Reports First Quarter 2019 Financial Results

Published

on

Reading Time: 12 minutes

Company Remains Focused on Five Pillars for Growth with Profitability
Plan to Drive Long-Term Profitable Growth

Provides Guidance for 2019, Including Adjusted EBITDA of $172 Million
to $178 Million

Announces Plan to Separate IP Licensing and Product Businesses into
Two Independent Companies

SAN JOSE, Calif.–(BUSINESS WIRE)–TiVo Corporation (NASDAQ: TIVO) today reported financial results for the
first quarter ended March 31, 2019. Earlier today, the Company also
announced a plan to split its Product and IP Licensing businesses into
two separate independent companies.

Advertisement
Stake.com

“We had a solid quarter with a strong focus on company execution,” said
Raghu Rau, Interim President and Chief Executive Officer. “Management
has, and will remain, focused on driving growth with profitability by
executing the previously announced five pillars of growth with
profitability strategy. On the product side, we announced our first IPTV
deployments of TiVo User Experience 4. Additionally, we are on track to
launch several new products and business models in the second half of
the year. On the Intellectual Property Licensing front, we continued to
demonstrate the strength of our patents internationally and validated
the value of our intellectual property in the social media space by
signing our first licensee in this rapidly growing market.”

“We are pleased that our Board has approved the separation of TiVo’s
Product and IP Licensing businesses and believe both businesses will be
better positioned independently. We believe the separation will unlock
shareholder value and increase our flexibility in pursuing new and
growing market opportunities. Throughout the separation process, the
Board of Directors will continue to be open to strategic transactions
for each business that could create additional stockholder value and is
actively engaged in discussions with interested parties for each
business,” continued Mr. Rau.

BUSINESS OUTLOOK

For fiscal year 2019, the Company expects revenue of $640 million to
$654 million, and a GAAP loss before taxes of $75 million to $87
million. Additionally, the Company expects Adjusted EBITDA of $172
million to $178 million and Non-GAAP Pre-tax Income of $120 million to
$126 million. TiVo anticipates it will incur $28 million to $29 million
in Cash Taxes based on its operating expectations. Additionally, TiVo
expects its GAAP Diluted weighted average shares outstanding to be
approximately 126 million and Non-GAAP Diluted Weighted Average Shares
Outstanding to be approximately 127 million.

CAPITAL ALLOCATION

Advertisement
Stake.com

On May 8, 2019, TiVo’s Board of Directors declared a cash dividend of
$0.08 per common share, to be paid on June 19, 2019 to stockholders of
record as of the close of business on June 5, 2019. In preparation for
the separation, the Board and management are focused on determining the
optimal strategy, operating structure and capital allocation policy for
each business. Accordingly, the Board felt it prudent to adjust the
current dividend in order to optimize our two balance sheets in advance
of the separation. While this is a lower dividend than in previous
quarters, it still provides a meaningfully higher yield than the S&P 500
average dividend yield.
     

FIRST QUARTER 2019 FINANCIAL HIGHLIGHTS

 
Quarterly Financial Information (In thousands)

Three Months Ended
March 31,

2019   2018 % Change
GAAP Consolidated Results
Total Revenues, net $ 158,235 $ 189,837

(17)

%

Advertisement
Stake.com
Total costs and expenses 166,255 198,877

(16)

%

Operating loss (8,020 ) (9,040 )

(11)

%

Loss from continuing operations before income taxes (20,326 ) (14,797 ) 37 %
Loss from continuing operations, net of tax (26,644 ) (19,014 ) 40 %
 
GAAP Diluted weighted average shares outstanding 124,422 122,080
 
Total Revenues, net $ 158,235 $ 189,837

(17)

Advertisement
Stake.com

%

Legacy TiVo Solutions IP Licenses (8,884 )

(100)

%

Hardware (2,074 ) (3,679 )

(44)

%

Advertisement
Stake.com
Other Products (364 ) (2,433 )

(85)

%

Core Revenue (excludes revenue from Legacy TiVo Solutions IP
Licenses, Hardware and Other Products)
$ 155,797   $ 174,841  

(11)

%

 

Total Revenues, net and Core Revenue decreased $31.6 million and $19.0
million, respectively, primarily due to $23.9 million of revenue
recognized from an international MSO customer exercising a contractual
option during Q1 2018 to purchase a fully paid license to its
then-current version of the TiVo software and purchasing additional
engineering services in the same period. These decreases were partially
offset by a new Passport agreement executed with an international MSO
customer during Q1 2019. In addition, Total Revenues, net decreased by
$8.9 million due to the expiration of the “Legacy Time Warp” agreements
that were entered into prior to the TiVo acquisition. The decrease in
Total costs and expenses was the result of lower Amortization of
intangible assets, the Company’s continuing cost reduction efforts and
the timing of patent litigation costs, primarily related to the ongoing
Comcast litigation.

Advertisement
Stake.com
     
(In thousands)

Three Months Ended
March 31,

2019   2018 % Change
Non-GAAP Consolidated Results
Adjusted EBITDA $ 37,441 $ 58,966 (37 )%
Non-GAAP Pre-tax Income 25,349 46,265 (45 )%
Cash Taxes 4,926 7,687 (36 )%
 
Non-GAAP Diluted Weighted Average Shares Outstanding 125,123 122,595
 

Adjusted EBITDA, Non-GAAP Pre-tax Income, Non-GAAP Diluted Weighted
Average Shares Outstanding and Cash Taxes are defined below in the
section entitled “Non-GAAP Financial Information.” Reconciliations
between GAAP and Non-GAAP amounts are provided in the tables below. In
accordance with the SEC’s interpretations on the use of Non-GAAP
financial measures, TiVo does not report net income or EPS on a non-GAAP
basis; however, TiVo provides financial metrics, including Non-GAAP
Pre-tax Income, Non-GAAP Diluted Weighted Average Shares Outstanding and
Cash Taxes, to assist those wanting to calculate such measures on a
Non-GAAP basis.
     

SEGMENT RESULTS AND OPERATING HIGHLIGHTS – PRODUCT

 
(In thousands)

Three Months Ended
March 31,

 
2019   2018 % Change
Platform Solutions $ 71,037 $ 95,940

(26)

Advertisement
Stake.com

%

Software and Services 19,902 18,479 8 %
Other 364   2,433  

(85)

%

Total Product Revenue, net 91,303 116,852

(22)

%

Advertisement
Stake.com
Adjusted Operating Expenses 82,890   89,466  

(7)

%

Adjusted EBITDA $ 8,413   $ 27,386  

(69)

%

Adjusted EBITDA Margin 9.2 % 23.4 %
 
Total Product Revenue, net $ 91,303 $ 116,852

(22)

Advertisement
Stake.com

%

Hardware (2,074 ) (3,679 )

(44)

%

Other Products (364 ) (2,433 )

(85)

%

Advertisement
Stake.com
Core Product Revenue (excludes revenue from Hardware and Other
Products)
$ 88,865   $ 110,740  

(20)

%

 

The $24.9 million decrease in Platform Solutions revenue and the $21.9
million decrease in Core Revenue was primarily attributable to a $23.9
million decrease in revenue recognized from an international MSO
customer who exercised a contractual option during Q1 2018 to purchase a
fully paid license to its then-current version of the TiVo software.

The decrease in Adjusted Operating Expenses primarily relates to reduced
spending on Research and Development due to cost saving initiatives and
benefits from decreases in Cost of hardware revenues as a result of
planned transition of our MSO partners and retail customers to deploying
TiVo service on third-party hardware.

Product Segment Operating Highlights:

Advertisement
Stake.com
  • Approximately 22 million subscriber households around the world use
    TiVo’s advanced television experiences.
  • RCN will power its next-generation solution with TiVo’s IPTV suite of
    products, including TiVo solutions for Android TVTM, TiVo
    for Streamers and TiVo for Mobile. This will enable the delivery of
    IPVOD, IP Linear, Restart, Catch-Up and Network DVR content to RCN
    subscribers.
  • Armstrong has chosen TiVo’s Next-Gen Platform that will enable a
    seamless transition to IPTV by deploying TiVo’s cloud-powered IPTV
    suite of solutions, including IPVOD, IP Linear, Restart, Catch-Up, and
    Network DVR, across a host of clients. In addition, Armstrong recently
    rolled out TiVo Experience 4 and voice-activated remote control
    functionality to its entire subscriber base.
  • Launched CubiTV™ Solutions for Android TV™, a modular, cost-effective,
    easy to deploy, pre-integrated solution with an intuitive
    operator-branded interface that taps into the power of Google
    Assistant search and browse functionality. Android TV is a trademark
    of Google LLC.
  • Service Electric Cable T.V. selected TiVo’s Next-Gen Platform to power
    its IP Linear services for streamers (Android TV, Apple TV and Fire
    TV) and for its mobile apps.
  • TiVo’s Passport Guide agreement with Cable Bahamas, a leading service
    provider and telecommunications in the region, was renewed.
  • TiVo has signed and renewed a number of Metadata agreements for
    customers in various industries, including leading players in music
    streaming, e-commerce and software, reaffirming the value of TiVo’s
    Metadata to market segments beyond the traditional broadcast networks
    and the electronic devices industries.
  • Redbox is deploying TiVo’s Personalized Content Discovery platform,
    including Search, Recommendations and Insights, as well as TiVo’s
    Video and Video Game Metadata across Redbox.com, Redbox On Demand
    streaming apps and physical boxes nationwide.
  • Funimation, a leading global anime content provider and a subsidiary
    of Sony Pictures Television (SPT), has licensed the Search,
    Recommendations and Insight modules of TiVo’s Personalized Content
    Discovery (PCD) platform.
  • TiVo’s TV Viewership Data continues to expand its customer base. Some
    of the customers that recently adopted this solution are:
    • Neustar, the leader in trusted customer identity and marketing
      analytics solutions for Fortune 500 brands.
    • A major broadcast and cable television network group.
    • VideoAmp, a software and data company that helps marketers and
      media owners optimize brand marketing against business results.
  • In the first quarter of 2019, we saw continued significant growth of
    TiVo’s PCD Conversation product. Monthly Active Users (MAU) in March
    2019 was 4.9 million, a 31% increase over the December 2018 MAU of 3.7
    million. Additionally, our Quarterly Voice API calls increased by 36%,
    growing from 238 million calls in Q4 2018 to 324 million in Q1 2019.
  • TiVo has expanded the footprint of the Sponsored Discovery advertising
    offering to include multiple MVPDs. Campaigns continue to drive strong
    performance: a major broadcast network ran a Sponsored Discovery
    campaign to promote a new series throughout its launch. The campaign
    increased tune-in by 436% to the series by those who saw the campaign.
     

SEGMENT RESULTS AND OPERATING HIGHLIGHTS – IP LICENSING

 
(In thousands)

Three Months Ended
March 31,

 
2019   2018 % Change
US Pay TV Providers $ 42,117 $ 49,915

(16)

%

CE Manufacturers 8,618 8,968

(4)

%

Advertisement
Stake.com
New Media, International Pay TV Providers and Other 16,197   14,102   15 %
Total IP Licensing Revenue, net 66,932 72,985

(8)

%

Adjusted Operating Expenses 21,807   25,357  

(14)

%

Adjusted EBITDA: $ 45,125   $ 47,628  

(5)

Advertisement
Stake.com

%

Adjusted EBITDA Margin 67.4 % 65.3 %
 
Total IP Licensing Revenue, net $ 66,932 $ 72,985

(8)

%

Legacy TiVo Solutions IP Licenses   (8,884 )

(100)

%

Advertisement
Stake.com
Core Intellectual Property Licensing Revenue (excludes revenue from
Legacy TiVo Solutions IP Licenses)
$ 66,932   $ 64,101   4 %
 

Intellectual Property Licensing revenue decreased 8% in the first
quarter. The $6.1 million decline in revenue is attributable to an $8.9
million decrease in revenue as a result of the expiration of the Legacy
Time Warp agreements, offset by increases in revenue from our existing
customers.

The decrease in Adjusted Operating Expenses relates to the timing of
patent litigation costs in the ongoing Comcast litigation.

Intellectual Property Licensing Segment Operating Highlights:

  • The Intellectual Property portfolio continues to demonstrate its
    relevance internationally with several multi-year renewals:
    • Humax, one of the world’s leading digital video gateway
      manufacturers, exporting its products to more than 90 countries
      across the globe, extended its intellectual property license
      agreement and included TiVo patents to its licensed portfolio.
    • TVStorm, a leading company of digital media service in Asia, has
      recently renewed its patent license agreement.
    • Dwango, a Japanese internet-based entertainment enterprise that
      offers a variety of digital content and services, renewed its
      patent license agreement.
  • In Q2, we signed a multi-year deal with a major social media company,
    our first in the growing space.

CONFERENCE CALL INFORMATION

TiVo management will host a conference call today, May 9, 2019, at 2:00
p.m. PT/5:00 p.m. ET to discuss the financial and operational results.
Investors and analysts interested in participating in the conference are
welcome to call (866) 621-1214 (or international +1-706-643-4013) and
reference conference ID 8759528. The conference call may also be
accessed via live webcast in the Investor Relations section of TiVo’s
website at http://ir.tivo.com.

A replay of the audio webcast will be available on TiVo’s website
shortly after the live call ends, and we currently plan for it to remain
on TiVo’s website until the next quarterly earnings call. Additionally,
a telephonic replay of the call will be accessible shortly after the
live call ends through May 16, 2019 by dialing (855) 859-2056 (or
international +1-404-537-3406) and entering conference ID 8759528.

Advertisement
Stake.com

NON-GAAP FINANCIAL INFORMATION

TiVo Corporation provides Non-GAAP information to assist investors in
assessing its operations in the way that its management evaluates those
operations. Non-GAAP Pre-Tax Income, Non-GAAP Cost of Licensing,
Services and Software Revenues, Non-GAAP Cost of Hardware Revenues,
Non-GAAP Research and Development Expenses, Non-GAAP Selling, General
and Administrative Expenses, Non-GAAP Depreciation, Non-GAAP Total OpEx
Excluding Goodwill Impairment, Non-GAAP Total OpEx, Non-GAAP Total COGS
and OpEx, Adjusted EBITDA and Non-GAAP Interest Expense are supplemental
measures of the Company’s performance that are not required by, and are
not determined in accordance with, GAAP. Non-GAAP financial information
is not a substitute for any financial measure determined in accordance
with GAAP.

Non-GAAP Pre-tax Income is defined as GAAP income (loss) from continuing
operations before income taxes, as adjusted for the effects of items
such as amortization of intangible assets, equity-based compensation,
accretion of contingent consideration, amortization or write-off of note
issuance costs, discounts on convertible debt and mark-to-market
adjustments for interest rate swaps and interest on escheat liabilities;
as well as items which impact comparability that are required to be
recorded under GAAP, but that the Company believes are not indicative of
its core operating results such as goodwill impairment, restructuring
and asset impairment charges, separation costs, transaction, transition
and integration costs, retention earn-outs payable to former
shareholders of acquired businesses, earn-out settlements, CEO
transition cash costs, remeasurement of contingent consideration, TiVo
acquisition litigation, expenses in connection with the extinguishment
or modification of debt, gain on settlement of acquired receivable,
additional depreciation resulting from facility rationalization actions,
other-than temporary impairment losses on strategic investments, gains
on the sale of strategic investments and changes in escheat liabilities.

Non-GAAP Cost of Licensing, Services and Software Revenues is defined as
GAAP Cost of licensing, services and software revenues, excluding
depreciation and amortization of intangible assets, excluding
equity-based compensation and transaction, transition and integration
expenses.

Non-GAAP Cost of Hardware Revenues is defined as GAAP Cost of hardware
revenues, excluding depreciation and amortization of intangible assets,
excluding equity-based compensation and transition and integration
expenses.

Advertisement
Stake.com

Non-GAAP Research and Development Expenses is defined as GAAP research
and development expenses excluding equity-based compensation, transition
and integration expenses and retention earn-outs payable to former
shareholders of acquired businesses.

Non-GAAP Selling, General and Administrative Expenses is defined as GAAP
selling, general and administrative expenses excluding equity-based
compensation, separation costs, transaction, transition and integration
expenses, retention earn-outs payable to former shareholders of acquired
businesses, earn-out settlements, CEO transition cash costs,
remeasurement of contingent consideration and gain on settlement of
acquired receivable.

Non-GAAP Depreciation is defined as GAAP depreciation expenses excluding
the impact of additional depreciation resulting from changes in the
estimated useful lives of assets involved in facility rationalization
actions.

Non-GAAP Total OpEx Excluding Goodwill Impairment is defined as GAAP
Total Operating costs and expenses excluding goodwill impairment.

Non-GAAP Total OpEx is defined as the sum of GAAP research and
development and selling, general and administrative expenses,
depreciation and gain on sale of patents excluding equity-based
compensation, separation costs, transaction, transition and integration
expenses, retention earn-outs payable to former shareholders of acquired
businesses, earnout settlements, CEO transition cash costs,
remeasurement of contingent consideration, gain on settlement of
acquired receivable and additional depreciation resulting from facility
rationalization actions.

Advertisement
Stake.com

Non-GAAP Total COGS and OpEx is defined as GAAP Total Operating costs
and expenses, excluding depreciation, amortization of intangible assets,
goodwill impairment, restructuring and asset impairment charges,
equity-based compensation, separation costs, transaction, transition and
integration expenses, retention earn-outs payable to former shareholders
of acquired businesses, earnout settlements, CEO transition cash costs,
remeasurement of contingent consideration and gain on settlement of
acquired receivable.

Adjusted EBITDA is defined as GAAP operating income (loss) excluding
depreciation, amortization of intangible assets, goodwill impairment,
restructuring and asset impairment charges, equity-based compensation,
separation costs, transaction, transition and integration costs,
retention earn-outs payable to former shareholders of acquired
businesses, earn-out settlements, CEO transition cash costs,
remeasurement of contingent consideration and gain on settlement of
acquired receivable.

Non-GAAP Interest Expense is defined as GAAP interest expense, excluding
accretion of contingent consideration, amortization or write-off of
issuance costs, discounts on convertible debt and interest on escheat
liability, plus the reclassification of the current period benefit
(cost) of the interest rate swaps from gain (loss) on interest rate
swaps.

Cash Taxes are defined as GAAP current income tax expense excluding
changes in reserves for unrecognized tax benefits.

Non-GAAP Diluted Weighted Average Shares Outstanding is defined as GAAP
diluted weighted average shares outstanding except for periods of a GAAP
loss. In periods of a GAAP loss, GAAP diluted weighted average shares
outstanding are adjusted to include dilutive common share equivalents
outstanding that were excluded from GAAP diluted weighted average shares
outstanding because the Company had a loss and therefore these shares
would have been anti-dilutive.

Advertisement
Stake.com

The Company’s management evaluates and makes decisions about its
business operations primarily based on Non-GAAP financial information.
Management uses Non-GAAP financial measures as the basis for
decision-making as they exclude items management does not consider to be
“core costs” or “core proceeds”. For each Non-GAAP financial measure,
the adjustment provides management with information about the Company’s
underlying operating performance that enables a more meaningful
comparison to its historical and projected financial performance in
different reporting periods. For example, since the Company does not
acquire or dispose of businesses on a predictable cycle, management
excludes the amortization of intangible assets, separation costs,
transition and integration costs, retention earn-outs payable to former
shareholders of acquired businesses, earnout settlements, CEO transition
cash costs, remeasurement of contingent consideration, TiVo Acquisition
litigation, and gain on settlement of acquired receivables from its
Non-GAAP financial measures in order to make more consistent and
meaningful evaluations of the Company’s operating expenses as these
items may be significantly impacted by the timing and magnitude of
acquisitions. Management also excludes the effect of goodwill
impairment, restructuring and asset impairment charges, expenses in
connection with the extinguishment or modification of debt, gain on the
settlement of acquired receivable, additional depreciation resulting
from facility rationalization actions, other-than-temporary impairment
losses on strategic investments, gains on the sale of strategic
investments and changes in escheat liability. Management excludes the
impact of equity-based compensation to provide meaningful supplemental
information that allows investors greater visibility to the underlying
performance of our business operations, facilitates comparison of our
results with other periods, and may facilitate comparison with the
results of other companies in our industry, as well as to provide the
Company’s management with an important tool for financial and
operational decision-making and for evaluating the Company’s performance
over different periods of time. Due to varying valuation techniques,
reliance on subjective assumptions and the variety of award types and
features that may be in use, we believe that providing Non-GAAP
financial measures excluding equity-based compensation allows investors
to make more meaningful comparisons between our operating results and
those of other companies. Management excludes the accretion of
contingent consideration, amortization or write-off of note issuance
costs and discounts on convertible debt, mark-to-market adjustments for
interest rate swaps and interest on escheat liability when management
evaluates the Company’s expenses. Management reclassifies the current
period benefit (cost) of the interest rate swaps from gain (loss) on
interest rate swaps to interest expense in order for Non-GAAP Interest
Expense to reflect the effects of the interest rate swaps as these
interest rate swaps were entered into to control the effective interest
rate the Company pays on its debt.

Management uses these Non-GAAP financial measures to help it make
decisions, including decisions that affect operating expenses and
operating margin. Management believes that making Non-GAAP financial
information available to investors, in addition to GAAP financial
information, may facilitate more consistent comparisons between the
Company’s performance over time with the performance of other companies
in our industry, which may use similar financial measures to supplement
their GAAP financial information.

Management recognizes that these Non-GAAP financial measures have
limitations as analytical tools, including the fact that management must
exercise judgment in determining which types of items to exclude from
the Non-GAAP financial information.

Contacts

Investor Relations
Debi Palmer
TiVo
Corporation
+1 818-295-6651
debi.palmer@tivo.com

Advertisement
Stake.com

Press Relations
Lerin O’Neill
TiVo
Corporation
+1 408-562-8455
lerin.oneill@tivo.com

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania